CClinicalTrials.gg
Not yet recruitingNCT06727123Updated Dec 10, 2024

The Effect of Motivational Interviewing on Diabetes Self-Management in Diabetic Patients

An interventional study of motivational interviewing and Control in Diabetes Mellitus, sponsored by University of Beykent. Not yet recruiting at 1 site in Turkey. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by University of Beykent · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Diabetes is a chronic metabolic disorder characterized by high blood sugar due to problems with insulin production or function. Its prevalence has increased significantly in recent decades due to sedentary lifestyles, unhealthy diets, and increasing obesity rates. Type 2 diabetes, in particular, is a major global and national health problem with projections showing that it continues to grow. Effective diabetes management requires patients to adopt healthy behaviors such as following a diet plan, monitoring blood sugar, increasing physical activity, and avoiding risky habits such as smoking. Inadequate adherence to treatment can lead to serious complications such as cardiovascular disease and kidney damage, which can be a burden to patients, families, and healthcare systems. Motivational interviewing, a patient-centered approach, helps individuals overcome resistance to behavioral change. This study was designed experimentally to determine the effect of motivational interviewing on diabetes self-management in patients with type 2 diabetes.

Read the detailed description

Diabetes is defined as a chronic metabolic disorder characterized by high blood sugar levels. Abnormalities in insulin production, function, or both are considered the primary causes of the disease. The epidemiology of diabetes has changed significantly over the last three decades. Diabetes mellitus is one of the most important health problems for both patients and society due to its high mortality, morbidity, and associated costs. The prevalence of diabetes continues to increase globally, driven by advances in technology, sedentary lifestyles, and increasing rates of obesity. Among these factors, the shift towards less active lifestyles plays a central role, with many individuals spending long periods sitting or engaging in low-energy activities. In addition, poor dietary habits, including increased consumption of high-calorie, processed foods, have increased the risk of developing diabetes, especially type 2 diabetes. In Turkey, the prevalence of type 2 diabetes reported in 2020 has shown a significant increase and is expected to increase further by 2050 if current trends continue. Effective treatment for diabetes requires patients to adopt positive attitudes and behaviors towards managing their health. However, many individuals have difficulty maintaining long-term lifestyle changes. Poor adherence to treatment plans and poor disease management often lead to a variety of complications, including acute and chronic health problems. These complications, such as cardiovascular disease, neuropathy, and kidney damage, impose a significant caregiving burden on individuals with diabetes, their families, and society as a whole. To alleviate these problems, individuals must engage in effective self-management to control their disease and prevent complications. Self-management refers to the individual's responsibility to maintain and improve their health. Diabetes self-management aims to normalize blood sugar levels and reduce the risk of long-term complications. Key practices include developing a personalized nutrition plan, monitoring blood sugar levels, maintaining metabolic control, increasing physical activity, and avoiding risky behaviors such as smoking or excessive alcohol consumption. Despite its importance, individuals living with diabetes often face challenges in adopting the lifestyle, behavioral, and psychological changes necessary for effective management. Motivational interviewing is an evidence-based approach that helps individuals resolve the dilemma of behavioral change and facilitates treatment adherence for chronic conditions such as diabetes. This patient-centered method emphasizes understanding the patient's unique challenges and goals, tailoring strategies to their specific needs, and encouraging autonomy. This study aims to evaluate the impact of motivational interviewing on diabetes self-management in patients with type 2 diabetes. It seeks to understand whether this approach can improve health outcomes by encouraging better adherence to treatment plans and supporting sustainable behavioral change, ultimately enhancing disease management in individuals coping with diabetes.

02

Conditions studied

  • Diabetes Mellitus

Browse trials for

Keywords

  • Diabetes Mellitus
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's planned enrollment of 80 is close to the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

University of Beykent is the lead sponsor of 54 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Individuals who agree to participate in the study voluntarily, can speak and understand Turkish, can communicate comfortably, have no hearing, comprehension or vision problems, are literate, use a smartphone, have Type 2 Diabetes and have HbA1c ≥ 7% will be included in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with cognitive dysfunction and those using antipsychotic medication will not be included.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Motivational Interviewing

    Motivational interviews will be conducted with diabetic patients for 6 months. Patients will be trained before starting the interviews.

    Other: motivational interviewing

  • Experimental
    Control

    No application will be made. Routine follow-ups will be made.

    Other: Control

Interventions

  • Othermotivational interviewing

    Motivational interviews will be conducted with diabetic patients for 6 months. Patients will be trained before starting the interviews.

  • OtherControl

    No application will be made. Routine follow-ups will be made.

06

What researchers measure

Primary outcomes

  1. Diabetes Self-Management

    Type 2 Diabetes Self-Management Scale

    Time frame: 6 months

Secondary outcomes

  1. HbA1c

    Routine blood value monitoring

    Time frame: 6 months

07

Study locations

1 site
  • Istanbul Beykent University
    Istanbul, Turkey
    • Sule Ç Calisir Kundakci, RN · Contact · sulecalisir@gmail.com · +905467873906
    • Sule Calisir Kundakci, RN · Principal investigator
    • Arzu Erkoc, PhD RN · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Sap, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06727123
Lead sponsor
University of Beykent
Responsible party
Sule Calisir Kundakci (Lecturer, University of Beykent) — Principal investigator
First posted
Dec 10, 2024
Start date
Dec 20, 2024 (estimated)
Primary completion
Dec 20, 2025 (estimated)
Completion
Jun 20, 2026 (estimated)
Last update
Dec 10, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion